Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Baxter
McKinsey
Dow
Merck

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR TROSPIUM CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Trospium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00465959 ↗ Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Alkermes, Inc. Phase 1/Phase 2 2007-04-01 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00465959 ↗ Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease Completed Endo Pharmaceuticals Phase 1/Phase 2 2007-04-01 To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD
NCT00800462 ↗ Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Ontario Neurotrauma Foundation Phase 4 2008-03-01 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
NCT00800462 ↗ Comparative Study of the Efficacy and Safety of Muscarinic M3 Receptors Antagonists in the Treatment of Neurogenic Detrusor Overactivity Completed Toronto Rehabilitation Institute Phase 4 2008-03-01 This is a phase IV, double-blind, multicenter, randomized trial evaluating the efficacy and safety of two M3 receptors antagonists (Trospium Chloride and Darifenacin Hydrobromide) with one standard drug (Oxybutynin Chloride) for treatment of overactive bladder in individuals with spinal cord injury.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trospium Chloride

Condition Name

Condition Name for Trospium Chloride
Intervention Trials
Schizophrenia 8
Overactive Bladder 5
Schizophrenia; Psychosis 2
Intestinal Obstruction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trospium Chloride
Intervention Trials
Schizophrenia 8
Urinary Bladder, Overactive 7
Intestinal Obstruction 2
Urinary Incontinence, Urge 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trospium Chloride

Trials by Country

Trials by Country for Trospium Chloride
Location Trials
United States 67
Germany 2
Canada 2
Ukraine 2
Egypt 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trospium Chloride
Location Trials
California 10
Texas 6
Ohio 6
New Jersey 5
Georgia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trospium Chloride

Clinical Trial Phase

Clinical Trial Phase for Trospium Chloride
Clinical Trial Phase Trials
Phase 4 6
Phase 3 7
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trospium Chloride
Clinical Trial Phase Trials
Completed 13
Recruiting 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trospium Chloride

Sponsor Name

Sponsor Name for Trospium Chloride
Sponsor Trials
Karuna Therapeutics 8
Allergan 5
Karuna Pharmaceuticals 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trospium Chloride
Sponsor Trials
Industry 19
Other 9
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Moodys
Johnson and Johnson
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.